iBio - IBIO Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iBio in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IBIO shares.
View IBIO analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 12 month price targets for iBio's stock. Their IBIO share price forecasts range from $37.50 to $37.50. On average, they anticipate the company's stock price to reach $37.50 in the next twelve months. This suggests a possible upside of 2,258.5% from the stock's current price.
View analysts price targets for IBIO or view top-rated stocks among Wall Street analysts.

iBio's stock was trading at $11.9650 at the beginning of the year. Since then, IBIO shares have decreased by 86.7% and is now trading at $1.59.
View the best growth stocks for 2022 here.

iBio saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 960,800 shares, an increase of 15.7% from the October 31st total of 830,100 shares. Based on an average daily volume of 136,400 shares, the short-interest ratio is currently 7.0 days. Approximately 11.0% of the company's shares are short sold.
View iBio's Short Interest.

iBio, Inc. (NYSEAMERICAN:IBIO) announced its quarterly earnings data on Monday, November, 15th. The biotechnology company reported ($1.00) EPS for the quarter, topping analysts' consensus estimates of ($1.25) by $0.25. The biotechnology company earned $0.21 million during the quarter. iBio had a negative trailing twelve-month return on equity of 74.73% and a negative net margin of 2,004.10%.

iBio's stock reverse split on Tuesday, October 11th 2022. The 1-25 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA).

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

iBio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (131.95%), BlackRock Inc. (75.47%), Renaissance Technologies LLC (14.30%), Ergoteles LLC (9.28%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Eastern Capital Ltd, James P Mullaney, Robert L Erwin and Robert Matthew Lutz.
View institutional ownership trends.

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IBIO stock can currently be purchased for approximately $1.59.

iBio (NYSEAMERICAN:IBIO) has a market capitalization of $14.33 million and generates $2.38 million in revenue each year. The biotechnology company earns $-50,300,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis.

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The official website for the company is www.ibioinc.com. The biotechnology company can be reached via phone at (302) 355-0650, via email at ir@ibioinc.com, or via fax at 302-356-1173.